Ionis Pharmaceuticals Future Growth
Future criteria checks 1/6
Ionis Pharmaceuticals is forecast to grow earnings and revenue by 32.5% and 18.2% per annum respectively. EPS is expected to grow by 32.8% per annum. Return on equity is forecast to be -185.8% in 3 years.
Key information
32.5%
Earnings growth rate
32.8%
EPS growth rate
Biotechs earnings growth | 26.4% |
Revenue growth rate | 18.2% |
Future return on equity | -185.8% |
Analyst coverage | Good |
Last updated | 30 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 1,107 | -280 | -244 | -117 | 15 |
12/31/2025 | 777 | -493 | -467 | -323 | 21 |
12/31/2024 | 620 | -568 | -499 | -406 | 23 |
12/31/2023 | 788 | -366 | -336 | -308 | N/A |
9/30/2023 | 615 | -409 | -574 | -541 | N/A |
6/30/2023 | 631 | -309 | -493 | -456 | N/A |
3/31/2023 | 576 | -329 | -405 | -377 | N/A |
12/31/2022 | 587 | -270 | -294 | -274 | N/A |
9/30/2022 | 875 | 7 | 110 | 130 | N/A |
6/30/2022 | 849 | -28 | 82 | 98 | N/A |
3/31/2022 | 841 | -4 | 35 | 54 | N/A |
12/31/2021 | 810 | -29 | 13 | 31 | N/A |
9/30/2021 | 661 | -608 | -96 | -75 | N/A |
6/30/2021 | 688 | -550 | -59 | -30 | N/A |
3/31/2021 | 708 | -495 | -45 | -11 | N/A |
12/31/2020 | 729 | -444 | -5 | 36 | N/A |
9/30/2020 | 933 | 94 | 173 | 216 | N/A |
6/30/2020 | 940 | 145 | 165 | 213 | N/A |
3/31/2020 | 959 | 169 | 188 | 230 | N/A |
12/31/2019 | 1,123 | 281 | 309 | 346 | N/A |
9/30/2019 | 821 | 433 | 154 | 183 | N/A |
6/30/2019 | 799 | 402 | 154 | 170 | N/A |
3/31/2019 | 752 | 366 | 679 | 697 | N/A |
12/31/2018 | 600 | 277 | 585 | 603 | N/A |
9/30/2018 | 575 | -41 | 485 | 508 | N/A |
6/30/2018 | 548 | -38 | 525 | 563 | N/A |
3/31/2018 | 543 | 9 | 28 | 65 | N/A |
12/31/2017 | 514 | 19 | 136 | 174 | N/A |
9/30/2017 | 507 | 42 | N/A | 127 | N/A |
6/30/2017 | 499 | 52 | N/A | 122 | N/A |
3/31/2017 | 426 | -15 | N/A | 86 | N/A |
12/31/2016 | 373 | -60 | N/A | -112 | N/A |
9/30/2016 | 238 | -184 | N/A | -123 | N/A |
6/30/2016 | 176 | -227 | N/A | -111 | N/A |
3/31/2016 | 258 | -134 | N/A | -12 | N/A |
12/31/2015 | 284 | -88 | N/A | 21 | N/A |
9/30/2015 | 317 | 14 | N/A | 129 | N/A |
6/30/2015 | 312 | 23 | N/A | 95 | N/A |
3/31/2015 | 249 | -24 | N/A | -4 | N/A |
12/31/2014 | 214 | -39 | N/A | 6 | N/A |
9/30/2014 | 172 | -94 | N/A | -79 | N/A |
6/30/2014 | 151 | -92 | N/A | -15 | N/A |
3/31/2014 | 132 | -90 | N/A | 42 | N/A |
12/31/2013 | 147 | -61 | N/A | 63 | N/A |
9/30/2013 | 125 | -39 | N/A | 114 | N/A |
6/30/2013 | 113 | -52 | N/A | 23 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0JDI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 0JDI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 0JDI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 0JDI's revenue (18.2% per year) is forecast to grow faster than the UK market (3.4% per year).
High Growth Revenue: 0JDI's revenue (18.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 0JDI is forecast to be unprofitable in 3 years.